TG Therapeutics, Inc. or Amneal Pharmaceuticals, Inc.: Who Invests More in Innovation?

Amneal vs. TG Therapeutics: R&D Investment Showdown

__timestampAmneal Pharmaceuticals, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 201410673500031354781
Thursday, January 1, 201513687000043445817
Friday, January 1, 201620474700066489820
Sunday, January 1, 201719193800096886134
Monday, January 1, 2018210451000153793000
Tuesday, January 1, 2019202287000148369000
Wednesday, January 1, 2020190585000151934000
Friday, January 1, 2021209563000198532000
Saturday, January 1, 2022200046000112128000
Sunday, January 1, 202316777800076192000
Loading chart...

Unveiling the hidden dimensions of data

Innovation Investment: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key. Over the past decade, Amneal Pharmaceuticals, Inc. and TG Therapeutics, Inc. have shown distinct strategies in their research and development (R&D) investments. From 2014 to 2023, Amneal consistently outpaced TG Therapeutics, investing approximately 70% more in R&D on average. Notably, in 2018, Amneal's R&D expenses peaked, reaching nearly double that of TG Therapeutics. However, TG Therapeutics demonstrated a remarkable growth trajectory, increasing its R&D spending by over 500% from 2014 to 2021. This surge highlights TG Therapeutics' commitment to innovation, despite its smaller scale. As the pharmaceutical landscape evolves, these investment patterns may shape the future breakthroughs and market positions of these companies. Understanding these trends offers valuable insights into the strategic priorities driving the pharmaceutical industry today.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025